Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, BioNexus Gene Lab Corp. reported revenue of $7M, down 21.9% year over year. Operating margin was -39.9% and net margin -40.2%, on a free-cash-flow margin of -25.3% with capital expenditure at 0.5% of revenue. Every figure is computed directly from BGLC's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $7M | -39.9% | -40.2% |
| FY2024 | $10M | -16.5% | -16.8% |
| FY2023 | $10M | -26.5% | -26.9% |
| FY2022 | $11M | -2.7% | -3.3% |
| FY2021 | $13M | 7.9% | 5.6% |
How does BGLC compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AACG · ABSI · ACCS · ACHC · ACM · ADUS
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.